How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,258 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. [A new beta-blocking agent in the treatment of chronic open-angle glaucoma: timolol maleate. Effect of instillation of 1 drop on the intraocular pressure]. (PubMed)

[A new beta-blocking agent in the treatment of chronic open-angle glaucoma: timolol maleate. Effect of instillation of 1 drop on the intraocular pressure]. A total of 45 patients with chronic open-angle glaucoma were divided randomly into three groups of fifteen. Each patient in each group was given one drop into one eye (the other eye serving as a control), of either placebo, timolol 0,5%, or timolol 1,5%. The patients were observed for a period of seven hours, and results showed that timolol (...) was effective in reducing ocular tension when compared to placebo. It was also rapid in action (one to two hours after instillation), and no side-effects were noted. Timolol 0,5% appears to be as equally effective as the 1,5% strength.

1978 Journal français d'ophtalmologie

102. An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle (Full text)

usage, participants were observed instilling eyedrops. Participants were instructed to instill a single eyedrop in each eye with both a standard bottle and the UEB. They repeated this process three times. With each trial, the amount of time taken to instill drops was recorded, as well as whether a drop landed in the eye (accuracy), if excess drops were used, and if the bottle tip was contaminated.Forty participants were enrolled, with an average age of 72.4±8.9 years; the majority were females (24 (...) females). Thirty-four participants had been using eyedrops for at least 1 year. The time required to instill eyedrops was significantly less with the UEB in the second and third trials. There was no difference in accuracy between the conventional bottle and the UEB in the left or right eye in any trials. Significantly more participants used excess number of drops while using the conventional bottle in both the left and right eyes in all three trials. The bottle tip was never contaminated with the UEB

2016 Clinical ophthalmology (Auckland, N.Z.) PubMed

103. Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

Conjunctival Allergen Challenge Model Actual Study Start Date : December 2016 Actual Primary Completion Date : February 2017 Actual Study Completion Date : November 2017 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Group 1 1X ST266 dosed 4 times a day for 8 days Biological: ST266 One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days. Placebo Comparator (...) : Group 2 Placebo dosed 4 times a day for 8 days Drug: Saline (0.9% NaCl) One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days. Outcome Measures Go to Primary Outcome Measures : Ocular itching [ Time Frame: Day 8 ] Ocular itching evaluated by the subject. Conjunctival redness [ Time Frame: Day 8 ] Conjunctival redness evaluated by the investigator. Secondary Outcome Measures : Ocular itching [ Time Frame: Day 7 ] Ocular itching evaluated by the subject

2016 Clinical Trials

104. Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops

Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Study Start Date : October 2015 Actual Primary Completion Date : March 2016 Actual Study Completion Date : March 2016 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: TheraTears Lubrication Drop TheraTears Lubricating Eye Drops to be instilled 1 drop in both eyes 4 times per day over a period of 8 weeks. Drug: TheraTears (...) Group Collaborator: Akorn, Inc. Information provided by (Responsible Party): Koffler Vision Group Study Details Study Description Go to Brief Summary: The objective of the study is to demonstrate a change in osmolarity over time when moderate to severe dry eye subjects are treated with TheraTears lubricating drops. Condition or disease Intervention/treatment Phase Dry Eye Syndrome Drug: TheraTears Lubricating Eye Drops Phase 4 Detailed Description: Symptomatic dry eye subjects exhibited

2016 Clinical Trials

105. A Clinical Randomized Trial Comparing the Cycloplegic Effect of Cyclopentolate Drops Applied to Closed Eyelids Versus Open Eyelids. (PubMed)

for annual refraction were enrolled. Three were excluded as they did not finish the testing. One drop of Alcaine® and one drop of cyclopentolate HCL 1% were used in each eye. Cyclopentolate drops were placed on the inner canthus near the lid margin on the closed eye and directly onto the conjunctiva of the fellow eye.Overall, 145/174 eyes (83%) were fully cyclopleged with one drop. The methods of instillation were equally successful (seventy-two indirect vs. seventy-three direct). Age, eye color (...) A Clinical Randomized Trial Comparing the Cycloplegic Effect of Cyclopentolate Drops Applied to Closed Eyelids Versus Open Eyelids. Adequate cycloplegia and dilation are required for refraction and fundus exam in children. Standard practice is to instill cycloplegic drops in the inferior cul-de-sac, and this is often traumatic for children. Our study assesses the use of cyclopentolate on closed lids as a method of instillation for ensuring complete cycloplegia.Ninety children presenting

2016 The American orthoptic journal

106. Post-operative ocular inflammation: A single sub-conjunctival injection of XG-102 compared to dexamethasone drops in a randomized trial. (Full text)

surgery were eligible to participate. Patients were administered a single subconjunctival injection of 250 μL XG-102 90 μg (n = 47) or 900 μg (n = 48) or placebo (n = 50) at the end of ocular surgery. Subconjunctival injection for each group (XG-102 90 μg, XG-102 900 μg, or placebo) was followed by eye drops instilled 4 times per day for 21 days with placebo, placebo, or dexamethasone solution, respectively. The primary outcome measure was anterior chamber cell grades at day 28 comparing XG-102 900 μg (...) Post-operative ocular inflammation: A single sub-conjunctival injection of XG-102 compared to dexamethasone drops in a randomized trial. To evaluate the efficacy and safety of XG-102 (brimapitide) compared to dexamethasone eye drops in the treatment of postoperative ocular inflammation.Multicenter, randomized, parallel group, double-masked, noninferiority clinical trial.Patients who underwent anterior and posterior segments combined surgery or glaucoma surgery or complex posterior segment

2016 American Journal of Ophthalmology PubMed

107. Effect of nepafenac eye drops on intraocular pressure - a randomized prospective study. (PubMed)

was randomized to the treatment group, with the other eye acting as a control. Nepafenac (0.1%) eye drops were instilled 3 times a day in the eye that received treatment. Intraocular pressure (IOP) with Goldmann applanation tonometer (GAT) was measured at baseline and at 4 and 8 weeks. Proportion of eyes with an IOP elevation of >4 mm Hg was the main outcome measure.The mean age of the participants was 45.7 ± 4.4 years. Participants included 192 female and 135 male patients. The mean IOP at baseline (...) Effect of nepafenac eye drops on intraocular pressure - a randomized prospective study. To report the effect of nepafenac (0.1%) eye drops on intraocular pressure in eyes with cataract.Prospective randomized clinical trial.Three hundred and twenty-seven patients with bilateral cataracts in an institutional setting were included. All patients had a baseline intraocular pressure (IOP) ≤ 21 mm Hg without a history of intraocular surgery in the past 3 months. One eye of each individual

2013 American Journal of Ophthalmology

108. Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. (Full text)

upon antioxidant/essential polyunsaturated fatty acid supplementation. Chronic instillation of antihypertensive eye drops must be considered for integrating protocols to glaucoma standards of care. (...) Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. Glaucoma and dry eye disorders (DEDs) are frequent comorbidities. The antioxidant and anti-inflammatory properties of essential polyunsaturated fatty acids have been extensively studied in relation to eye diseases.Our objective was to determine the effects of oral supplementation

2013 Clinical interventions in aging PubMed

109. Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects

administered Olixia pure® eye drops on tear film thickness in healthy subjects. Tear film thickness will be determined using ultra high-resolution optical coherence tomography (OCT). Measurements will be performed before instillation of the eye drops and every 10 minutes after instillation for one hour. One eye will receive Olixia pure® eye drops, the fellow eye will receive physiologic saline solution as placebo control. The study eye will be chosen randomly. Condition or disease Intervention/treatment (...) Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2013 Clinical Trials

110. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension. (PubMed)

. At baseline and 12 weeks, patients demonstrated drop instillation using a bottle of artificial tears.Patient self-assessment of difficulty with drop administration and observed patient difficulty with drop administration, defined as bottle touching eye/adnexa, drop missing the ocular surface, or administering more than 1 drop.Of 164 enrolled patients, 50% had previously been treated with ocular hypotensive medication for ≥3 years. Only 11.4% of patients reported difficulty with eye drop administration (...) at study entry. At baseline, 18.2% of patients touched their eye/adnexa with the bottle and 10.3% missed the eye. At 12 weeks, 18.5% and 8.6% of patients, respectively, had similar difficulties. Overall, difficulty with drop instillation was observed in 42.1% of patients. Difficulty at both visits was seen in 35.3% of patients who reported difficulty at entry and in 17.2% of patients who denied difficulty. The relative risk of demonstrating difficulty at either visit was 2.0 times greater for patients

2013 Current medical research and opinion

111. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension.

. At baseline and 12 weeks, patients demonstrated drop instillation using a bottle of artificial tears.Patient self-assessment of difficulty with drop administration and observed patient difficulty with drop administration, defined as bottle touching eye/adnexa, drop missing the ocular surface, or administering more than 1 drop.Of 164 enrolled patients, 50% had previously been treated with ocular hypotensive medication for ≥3 years. Only 11.4% of patients reported difficulty with eye drop administration (...) at study entry. At baseline, 18.2% of patients touched their eye/adnexa with the bottle and 10.3% missed the eye. At 12 weeks, 18.5% and 8.6% of patients, respectively, had similar difficulties. Overall, difficulty with drop instillation was observed in 42.1% of patients. Difficulty at both visits was seen in 35.3% of patients who reported difficulty at entry and in 17.2% of patients who denied difficulty. The relative risk of demonstrating difficulty at either visit was 2.0 times greater for patients

2013 Current medical research and opinion

112. Dry eye syndrome

made. June 2012 — minor update. Typographical error corrected. March 2011 — technical update. The management section of this topic has been simplified to improve clarity and navigation. There have been no changes to the clinical content or meaning of the recommendations. September 2010 — minor update. Hydromoor® (hypromellose 0.3% preservative-free single dose eye drops) have been included. Issued in September 2010. March 2010 — minor update. Lubri-Tears® eye ointment has been discontinued (...) . Prescription removed. Issued in March 2010. December 2007 to March 2008 — converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Although there is a new section on assessment, there are no major changes to the recommendations. January 2006 — minor update. Black triangle removed from carmellose sodium eye drops. Issued in February 2006. September 2004 — reviewed

2017 NICE Clinical Knowledge Summaries

113. Comparison of three lubricant eye drop solutions in dry eye patients. (PubMed)

Comparison of three lubricant eye drop solutions in dry eye patients. Lubricant eye drops that restore physiological osmolarity represent a promising strategy for dry eye syndrome as hyperosmolarity plays a central role in this disease. This preliminary study compared three lubricant eye drop solutions with different osmolarities and compositions in subjects with this condition.Subjects with dry eye syndrome undergoing treatment with benzalkonium chloride-containing lubricant eye drops were (...) Optive and Blu Sal in subjects with dry eye syndrome over a 1 h period, possibly because of its hypo-osmolarity and high osmolyte (in particular L-carnitine) content. The instillation of compounds that improve the quality and stability of the tear film, which are impaired in dry eye syndrome, could be effective in the treatment of this condition.

2011 Optometry and vision science : official publication of the American Academy of Optometry

114. Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

2012 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Thymosin Beta 4 eye drops It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, six times daily for 28 days Drug: Thymosin Beta 4 eye drops Patients will be randomized and will receive the same eye drops the Thymosin Beta 4. Other Name: Tβ4 Placebo Comparator: Vehicle Control (...) It is composed of the same excipients as RGN-259 but does not contain Tβ4 for direct instillation into each eye, six times daily for 28 days. Drug: Vehicle Control Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4. Other Name: Vehicle Outcome Measures Go to Primary Outcome Measures : Safety [ Time Frame: Day 1, Day 14, Day 28 and Day 56 ] Sum of adverse events observed at Day 1, Day 14, Day 28 and Day 56. Measurable by Intra-ocular pressure (IOP) by applanation

2011 Clinical Trials

115. In suspected corneal foreign body should local anaesthetic be applied before or after eye examination?

Royal Infirmary, Manchester, UK Date Submitted: 9th February 2015 Date Completed: 1st July 2015 Last Modified: 1st July 2015 Status: Green (complete) Three Part Question In [a patient presenting with a suspected corneal foreign body] is [instillation of anaesthetic drops before eye examination better than installation after eye examination] at [allowing identification and removal of any foreign bodies]? Clinical Scenario A 47-year-old man presents complaining of a painful gritty sensation within his (...) left eye. He had been taking down a ceiling in his house and had not been wearing eye protection. You suspect a corneal foreign body. You are about to instil local anaesthetic drops when your registrar suggests that this is not necessary since, if there is a foreign body and it is subtarsal it could be removed without the need for the drops. She points out that installation of local anaesthetic drops is not without risk. You wonder if there is any evidence to support her pragmatic view. Search

2015 BestBETS

116. Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears

The technology 2.1 Ciclosporin (Ikervis, Santen Pharmaceutical) is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion that contains ciclosporin (CsA). Its formulation contains an excipient, cetalkonium chloride, which acts as a cationic agent and is specifically designed to prolong the time each eye drop stays on the epithelial layer of the eye. Ciclosporin has an anti-inflammatory effect on the cornea and the lacrimal (tear) gland. Following administration, ciclosporin blocks (...) the expression of pro-inflammatory cytokines and subsequently enters corneal and conjunctival infiltrated T-cells, activating them. It has a marketing authorisation in the UK for treating 'severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes' . Ciclosporin is administered as an eye drop of 1 mg/ml once daily at bed time. 2.2 The acquisition cost of a monthly course of ciclosporin is £72 (excluding VAT). Costs may vary in different settings

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

117. Abusive Head Trauma and the Eye in Infancy

Abusive Head Trauma and the Eye in Infancy 1 The Royal College of Paediatrics and Child Health and The Royal College of Ophthalmologists Abusive Head Trauma and the Eye in Infancy June 2013 Scientific Department The Royal College of Ophthalmologists 17 Cornwall Terrace Regent’s Park London NW1 4QW Telephone: 020 7935 0702 Facsimile: 020 7487 4674 www.rcophth.ac.uk © The Royal College of Ophthalmologists 2013 All rights reserved For permission to reproduce any of the content contained herein (...) baby syndrome 35. SIGN Scottish intercollegiate guidelines network 36. SDH Subdural haemorrhage 7 Guideline Working Party (GWP) Chairman Patrick Watts, Consultant Ophthalmologist, Cardiff, Wales Working Party Gillian Adams Consultant Ophthalmologist, Moorfields Eye Hospital London John Ainsworth Consultant Ophthalmologist, Children’s Hospital, Birmingham Susmito Biswas Consultant Ophthalmologist, Children’s Hospital, Manchester Richard Bonshek Consultant Pathologist, Manchester Royal Eye Hospital

2013 Royal College of Ophthalmologists

118. [Comparison of objective optical quality measured by double-pass aberrometry in patients with moderate dry eye: Normal saline vs. artificial tears: A pilot study]. (PubMed)

quality of vision measured by OQAS between treatment with normal saline eye drops and treatment with carmellose 0.5% and hyaluronic acid 0.1% (Optive Fusion [OF], Allergan) in patients with moderate dry eye syndrome. Optical quality was measured by evaluating the variations in the Optical Scattering Index (OSI) over 20seconds using the OQAS. Inclusion criteria were dry eye syndrome with an Ocular Surface Disease Index (OSDI) score>23 treated only with artificial tears. The patients were their own (...) controls: OF in one eye and normal saline in the fellow eye. The choice of the subject eye and control eye was determined in a randomized fashion. OSI variations were measured in each eye before instillation, 5minutes and 2hours after instillation. The primary endpoint was OSI fluctuation over 20seconds of measurement. Secondary endpoints were the number of blinks and patient's preference (preferred eye). Preliminary results were obtained on 19 patients. Average OSDI score was 36.8. Visual acuity

2018 Journal francais d'ophtalmologie

119. Comparison of objective optical quality measured by double-pass aberrometry in patients with moderate dry eye: Normal saline vs. artificial tears: A pilot study. (PubMed)

of vision measured by OQAS between treatment with normal saline eye drops and treatment with carmellose 0.5% and hyaluronic acid 0.1% (Optive Fusion [OF], Allergan) in patients with moderate dry eye syndrome. Optical quality was measured by evaluating the variations in the Optical Scattering Index (OSI) over 20seconds using the OQAS. Inclusion criteria were dry eye syndrome with an ocular surface disease index (OSDI) score >23 treated only with artificial tears. The patients were their own controls (...) : OF in one eye and normal saline in the fellow eye. The choice of the subject eye and control eye was determined in a randomized fashion. OSI variations were measured in each eye before instillation, 5minutes and 2hours after instillation. The primary endpoint was OSI fluctuation over 20seconds of measurement. Secondary endpoints were the number of blinks and patient preference (preferred eye). Preliminary results were obtained on 19 patients. Average OSDI score was 36.8. Visual acuity was 10/10

2018 Journal francais d'ophtalmologie

120. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease. (PubMed)

and the score at 3 min improved across visits (12-week trials (both eyes, day 84 vs 0): 2.0 vs 3.3; SONATA (day 360 vs 0): right eye, 1.2 vs 1.7; left eye, 1.2 vs 1.8).Lifitegrast ophthalmic solution 5.0% appeared to be safe and well tolerated for the treatment of dry eye disease. Drop comfort with lifitegrast improved within 3 min of instillation. (...) (0-4 scale)). Participants were randomized to lifitegrast ophthalmic solution 5.0% or placebo twice daily for 84 or 360 days. Treatment-emergent adverse events and drop comfort scores were assessed.Overall, 2464 participants (lifitegrast, n = 1287; placebo, n = 1177) were included. Ocular treatment-emergent adverse events occurring in >5% in either group were instillation site irritation (lifitegrast, 15.2%; placebo, 2.8%), instillation site reaction (lifitegrast, 12.3%; placebo, 2.3

2018 European journal of ophthalmology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>